The Latest Breaking News from Pfizer

Pfizer Inc (NYSE:PFE) will acquire Biohaven Pharmaceutical Holding Company Ltd (NYSE:BHVN) for $148.50 per share, equivalent to $11.6 billion.  Pfizer will also make payments at closing to settle Biohaven's third-party debt and for the redemption of all outstanding shares of Biohaven's redeemable preferred stock.  The deal includes the acquisition of rimegepant (NURTEC ODT), a dual-acting…

Pfizer is spending $11.6 billion to buy the remaining portion of migraine treatment maker Biohaven Pharmaceuticals it does not already own

It is "over and above" the level of protection that people who have had their third jab receive, according to the latest research.

Chance of stillbirth reduced by 15%, researchers find, after examining studies and trials that enrolled 117,552 women

Levels of antibodies waned in period between third jabs and fourth boosters

A ‘hint’ that some people might have already reached ‘ceiling’ in terms of protection they could acquire from fourth jab

UK-based team finds antibodies peaked higher after fourth jab given after gap of more than six months than after third

Academics have been monitoring the levels of protection post-vaccination.

A 12-year-old boy in Phuket did not lose his sight because of Pfizer's coronavirus vaccine but due to severe complications from sinusitis, medical experts on the island province said.

For Australians at high risk of developing severe COVID-19, getting access to potentially lifesaving treatments recently became easier — but experts say some people are still having trouble obtaining them.

A small number of COVID-19 patients are relapsing after taking Pfizer's antiviral pill, raising questions about the drug at the center of the U.S. response effort